Os Therapies
Cambridge, Maryland, United States · Biopharma, Biotechnology, Healthcare
OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors.
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Cambridge, Maryland, United States
- Employees
- 5
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Public (OSTX)
- Website
- ostherapies.com
- Company page
Recent activity at Os Therapies
- : OS Therapies Appoints Mr. Clem as Chief Commercial Officer and Mr. Knuettel as Chief Financial Officer
- : SEC 8-K (8.01): On September 10, 2026, OS Therapies Incorporated filed a prospectus supplement with the SEC, part of its registration statement on Form S-3. This supplement pertains to the resale of up to 5,874,094 shares of common stock by the identified selling stockholders. The filing includes a legal opinion from Olshan Frome Wolosky LLP concerning the legality of the shares being offered. This event is significant as it indicates ongoing opportunities for shareholders to divest holdings, which could impact market liquidity and shareholder dynamics. The effective registration statement was previously filed on August 8, 2025, and declared effective on August 25, 2025.
- : SEC 8-K (5.02): On September 9, 2026, stockholders of OS Therapies Incorporated approved an amendment and restatement of the company’s 2023 Incentive Compensation Plan during the Annual Meeting. This Amended and Restated Plan introduces significant updates aimed at optimizing the company's incentive structure for its executives and directors. The details of these amendments are thoroughly discussed in the Proxy Statement filed with the SEC on July 24, 2026. The approval reflects the company's commitment to enhancing its governance and compensatory practices to align with shareholder interests.
About Os Therapies: questions and answers
What does Os Therapies do?
OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors.
Where is Os Therapies headquartered?
Os Therapies is headquartered in Cambridge, Maryland, United States.
How many employees does Os Therapies have?
Os Therapies has about 5 employees.
What is the latest news on Os Therapies?
On Oct 01, 2026, OS Therapies Appoints Mr. Clem as Chief Commercial Officer and Mr. Knuettel as Chief Financial Officer
Is Os Therapies a public company?
Yes. Os Therapies is publicly traded under the ticker OSTX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy